JP5091876B2 - 癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのＰｒｏＮＧＦアッセイのための方法とＰｒｏＮＧＦの治療的使用 - Google Patents

癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのＰｒｏＮＧＦアッセイのための方法とＰｒｏＮＧＦの治療的使用 Download PDF

Info

Publication number
JP5091876B2
JP5091876B2 JP2008552858A JP2008552858A JP5091876B2 JP 5091876 B2 JP5091876 B2 JP 5091876B2 JP 2008552858 A JP2008552858 A JP 2008552858A JP 2008552858 A JP2008552858 A JP 2008552858A JP 5091876 B2 JP5091876 B2 JP 5091876B2
Authority
JP
Japan
Prior art keywords
prongf
cancer
cells
breast
thyroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008552858A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009525478A5 (https=
JP2009525478A (ja
Inventor
ジュヌヴィエーヴ ショケ−カスティルヴスキ，
ヨアン ドゥモン，
ウベール オンデルマルク，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomerieux SA
Original Assignee
Biomerieux SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomerieux SA filed Critical Biomerieux SA
Publication of JP2009525478A publication Critical patent/JP2009525478A/ja
Publication of JP2009525478A5 publication Critical patent/JP2009525478A5/ja
Application granted granted Critical
Publication of JP5091876B2 publication Critical patent/JP5091876B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/48—Nerve growth factor [NGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2008552858A 2006-01-31 2007-01-30 癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのＰｒｏＮＧＦアッセイのための方法とＰｒｏＮＧＦの治療的使用 Active JP5091876B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0600851A FR2896881B1 (fr) 2006-01-31 2006-01-31 Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie
FR0600851 2006-01-31
PCT/FR2007/050708 WO2007088305A1 (fr) 2006-01-31 2007-01-30 Procede de dosage du prongf pour le diagnostic in vitro du cancer en particulier du cancer du sein, de la thyroide ou du poumon et utilisation du prongf en therapie

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012124525A Division JP5792121B2 (ja) 2006-01-31 2012-05-31 癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのＰｒｏＮＧＦアッセイのための方法とＰｒｏＮＧＦの治療的使用

Publications (3)

Publication Number Publication Date
JP2009525478A JP2009525478A (ja) 2009-07-09
JP2009525478A5 JP2009525478A5 (https=) 2010-03-04
JP5091876B2 true JP5091876B2 (ja) 2012-12-05

Family

ID=36741378

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008552858A Active JP5091876B2 (ja) 2006-01-31 2007-01-30 癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのＰｒｏＮＧＦアッセイのための方法とＰｒｏＮＧＦの治療的使用
JP2012124525A Active JP5792121B2 (ja) 2006-01-31 2012-05-31 癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのＰｒｏＮＧＦアッセイのための方法とＰｒｏＮＧＦの治療的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012124525A Active JP5792121B2 (ja) 2006-01-31 2012-05-31 癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのＰｒｏＮＧＦアッセイのための方法とＰｒｏＮＧＦの治療的使用

Country Status (7)

Country Link
US (3) US8008009B2 (https=)
EP (1) EP1982192B1 (https=)
JP (2) JP5091876B2 (https=)
CN (2) CN103446585A (https=)
ES (1) ES2471126T3 (https=)
FR (1) FR2896881B1 (https=)
WO (1) WO2007088305A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2896881B1 (fr) * 2006-01-31 2008-04-18 Biomerieux Sa Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
EP2806054A1 (en) 2008-05-28 2014-11-26 Genomedx Biosciences Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
FR2944019B1 (fr) * 2009-04-03 2011-04-22 Biomerieux Sa Procede de dosage de la prodefensine-a6 pour le diagnostic in vitro du cancer colorectal.
US8669057B2 (en) 2009-05-07 2014-03-11 Veracyte, Inc. Methods and compositions for diagnosis of thyroid conditions
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
CN101782585A (zh) * 2010-02-10 2010-07-21 广州医学院 肺癌组织蛋白印迹膜片及其制备方法
US20130115222A1 (en) * 2010-06-15 2013-05-09 Cornell University Methods of limiting microvascular damage following acute myocardial ischemia
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
US20140295426A1 (en) * 2011-07-28 2014-10-02 Veridex Llc Methods for Diagnosing Cancer by Characterization of Tumor Cells Associated with Pleural or Serous Fluids
EP2791359B1 (en) 2011-12-13 2020-01-15 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
DK3435084T3 (da) 2012-08-16 2023-05-30 Mayo Found Medical Education & Res Prostatakræftprognose under anvendelse af biomarkører
CN103122390B (zh) * 2013-03-07 2015-04-08 上海市疾病预防控制中心 Frat1基因作为检测甲状腺癌的血清标志物及其应用
EP3626308A1 (en) 2013-03-14 2020-03-25 Veracyte, Inc. Methods for evaluating copd status
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
CN103866039B (zh) * 2014-04-04 2015-05-27 厦门大学 人类甲状腺癌组织基因特异位点甲基化水平检测引物及其应用
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
EP2977759B1 (en) * 2014-07-25 2017-07-12 Serum Institute of India Private Limited Highly sensitive immunoassay for rapid quantification of meningococcal capsular polysaccharide antigens
EP3215170A4 (en) 2014-11-05 2018-04-25 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
CN107708733B (zh) 2015-04-07 2022-11-15 艾利妥 抗分拣蛋白抗体和其使用方法
US10849992B1 (en) 2015-04-07 2020-12-01 Alector Llc Methods of screening for sortilin binding antagonists
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
EP3571322B9 (en) 2017-01-20 2023-10-04 VERACYTE SD, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
JP2020508643A (ja) * 2017-01-24 2020-03-26 ジェネティック テクノロジーズ リミテッド 乳癌発症リスクの改良された評価法
EP3593140A4 (en) 2017-03-09 2021-01-06 Decipher Biosciences, Inc. SUBTYPING PROSTATE CANCER TO PREDICT RESPONSE TO HORMONE THERAPY
CA3062716A1 (en) 2017-05-12 2018-11-15 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
CA3066507A1 (fr) * 2017-06-08 2018-12-13 Carcidiag Biotechnologies Methode d'isolement et de detection de cellules souches cancereuses
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
WO2019028285A2 (en) 2017-08-04 2019-02-07 Genomedx, Inc. USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY
TWI809147B (zh) 2018-07-13 2023-07-21 美商阿列克特有限責任公司 抗分揀蛋白抗體及其使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548062B2 (en) 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
AU2003242815A1 (en) 2002-03-13 2003-09-22 Biomerieux Method for the characterisation of circulating tumour cells stemming from solid cancers
FR2846426B1 (fr) 2002-10-28 2004-12-10 Bio Merieux Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
AU2003287930A1 (en) * 2002-12-20 2004-07-14 Neuronicon Aps Modulation of activity of neurotrophins
WO2005076695A2 (en) * 2004-02-11 2005-08-25 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity
FR2896881B1 (fr) * 2006-01-31 2008-04-18 Biomerieux Sa Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie

Also Published As

Publication number Publication date
JP2012211148A (ja) 2012-11-01
US20110293636A1 (en) 2011-12-01
WO2007088305A1 (fr) 2007-08-09
CN101395478A (zh) 2009-03-25
JP5792121B2 (ja) 2015-10-07
CN103446585A (zh) 2013-12-18
JP2009525478A (ja) 2009-07-09
FR2896881A1 (fr) 2007-08-03
EP1982192A1 (fr) 2008-10-22
US9061045B2 (en) 2015-06-23
US20130171173A1 (en) 2013-07-04
ES2471126T3 (es) 2014-06-25
FR2896881B1 (fr) 2008-04-18
US20090068200A1 (en) 2009-03-12
US8008009B2 (en) 2011-08-30
EP1982192B1 (fr) 2014-03-26
CN101395478B (zh) 2013-08-28

Similar Documents

Publication Publication Date Title
JP5091876B2 (ja) 癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのＰｒｏＮＧＦアッセイのための方法とＰｒｏＮＧＦの治療的使用
US8101713B2 (en) Prostate cancer diagnosis and treatment
Nitori et al. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma
Rajamanickam et al. Selective targeting of the TLR4 co-receptor, MD2, prevents colon cancer growth and lung metastasis
US20110111431A1 (en) Method for identifying pre-neoplastic and/or neoplastic states in mammals
US20160208008A1 (en) Monoclonal antibodies to transferrin and transferrin receptor antigens, and uses thereof
EP3287143A1 (en) Ckap4-molecular-targeted antitumor agent
Wei et al. Activation of vitamin D/VDR signaling reverses gemcitabine resistance of pancreatic cancer cells through inhibition of MUC1 expression
AU2003285472B2 (en) Method for NGF assay for in vitro diagnosis of breast cancer and therapeutic use
Gu et al. Expression of thymosin β10 and its role in non–small cell lung cancer
Wu et al. Chronic stress-induced ANPEP drives liver cancer progression by increasing glutathione synthesis and inhibiting ferroptosis
US20240174762A1 (en) Methods, compositions and uses for targeting sema7a in the diagnosis and treatment of health conditions
US7026454B1 (en) Neuroendocrine marker of prostate cancer and method for producing same
He et al. Local blockage of self-sustainable erythropoietin signaling suppresses tumor progression in non-small cell lung cancer
Wei et al. Activation of vitamin D/VDR signaling reverses gemcitabine resistance of pancreatic cancer cells through inhibition of MUC1 expression
CN118252922A (zh) Sirt6激活剂mdl-800在乳腺癌逆转治疗抵抗与化疗耐药中的应用
KR20110122468A (ko) 재발암, 내성암 또는 암전이 치료용 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100108

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20111214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120427

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120604

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120821

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120914

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150921

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5091876

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250